Sound waves zapping skin cancer? new trial tests HIFU for basal cell carcinoma
NCT ID NCT05133427
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a new device that uses high-intensity focused ultrasound (HIFU) to treat basal cell carcinoma, the most common skin cancer. Forty adults with either new or recurring skin cancers will receive a single 3-5 minute treatment. Researchers will check if the cancer is gone after 3 months and monitor side effects for one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
High-intensity focused ultrasound (HIFU) device
What this could lead to
If successful, this could offer a quick, non-invasive treatment for common skin cancers without surgery.
What could go wrong
This is a small early-stage trial with only 40 people. The treatment may not fully remove the cancer or could cause side effects like scarring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, BASAL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bispebjerg Hospital
Copenhagen, Capital Region, 2400, Denmark
-
Roskilde Hospital
Roskilde, Region Sjælland, 4000, Denmark